Aura Biosciences, Inc.
Aura Biosciences, Inc.
Your view on AURA
Overview
What the company does, where it operates, and who runs it.
About Aura Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Elisabet de los Pinos
- Headquarters
- 85 Bolton Street, Boston, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Elisabet de los Pinos
- Headquarters
- 85 Bolton Street, Boston, MA, US
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Aura Biosciences, Inc., and the rating behind it. AURA last traded at $7.00; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Aura Biosciences, Inc.. Starting points for Aura Biosciences, Inc.: EPS -$1.38, beta 0.40 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Aura Biosciences, Inc.. Aura Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Aura Biosciences, Inc.. Trailing twelve-month EPS for Aura Biosciences, Inc. stands at -$1.38. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Aura Biosciences, Inc.. Aura Biosciences, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Aura Biosciences, Inc. valued side by side against its closest peers. Aura Biosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Aura Biosciences, Inc., and how their positions are changing. At a $723.5M market value, institutional positions materially move Aura Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Aura Biosciences, Inc. executives and directors. Shares of Aura Biosciences, Inc. have traded between $4.34 and $9.53 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Aura Biosciences, Inc.. Aura Biosciences, Inc. is a $723.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Aura Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Aura Biosciences, Inc.. Coverage tracks Aura Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.